Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22336795 | 0.84 | ATM (0.53) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL20176146 | 0.80 | ATM (0.49) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL21568863 | 0.72 | L3MBTL1 (0.71) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL21568864 | 0.72 | L3MBTL1 (0.66) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL12435378 | 0.72 | ATM (0.65) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL19060868 | 0.71 | L3MBTL1 (0.72) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL24242445 | 0.70 | ATM (0.63) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL16258744 | 0.70 | ATM (0.57) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL4566692 | 0.70 | ATM (0.63) | ATML3MBTL1KMT2AMEN1TDP1 | |
| SCHEMBL19574089 | 0.70 | ATM (0.95) | ATML3MBTL1KMT2AMEN1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | ATM 1164/4885L3MBTL1 1911/4885KMT2A 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.